Compare Cassava Sciences Inc (FLNA) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ralph Lauren Corp — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Ralph Lauren Corp trades at $368.77 (market cap $21.52B). The key difference: Ralph Lauren Corp is far larger — about 546.2× Cassava Sciences Inc's market cap, and Ralph Lauren Corp pays a 1.11% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Ralph Lauren Corp for 84 Days on average.
| FLNA | RL | |
|---|---|---|
Market Cap | $39.40M | $21.52B |
Volume | 759,018 | 454,217 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $414.25 |
52-Week Low | $0.68 | $309.29 |
Typical Hold Time | 37 Days | 84 Days |
Enterprise Value | -$43.28M | $22.58B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Ralph Lauren (RL) trades at $367.39, down 0.35% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 70.27% gross margins and 37.54% ROE, while consistently beating earnings estimates. Recent news highlights global expansion through new store openings and AI-driven customer experience enhancements. Cash flow remains positive at $258.80M for 2025, supporting the $1.00 dividend declared for October 2026 payment.
The stock presents a compelling value opportunity with analyst consensus target of $456.67 representing 24% upside. Strong brand positioning and operational efficiency drive growth, though competitive pressures and market volatility pose risks. Institutional sentiment remains bullish with 67% buy ratings, suggesting confidence in the company's luxury market strategy and financial performance trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
